The transcript of the chairman’s address to the Annual General Meeting of Shareholders, for the financial year ending December 2020, is now available.
Please click to review the transcript at ASX.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
February 19, 2025
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce